Choudhri T F, Hoh B L, Zerwes H G, Prestigiacomo C J, Kim S C, Connolly E S, Kottirsch G, Pinsky D J
College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA.
J Clin Invest. 1998 Oct 1;102(7):1301-10. doi: 10.1172/JCI3338.
Treatment options in acute stroke are limited by a dearth of safe and effective regimens for recanalization of an occluded cerebrovascular tributary, as well as by the fact that patients present only after the occlusive event is established. We hypothesized that even if the site of major arterial occlusion is recanalized after stroke, microvascular thrombosis continues to occur at distal sites, reducing postischemic flow and contributing to ongoing neuronal death. To test this hypothesis, and to show that microvascular thrombosis occurs as an ongoing, dynamic process after the onset of stroke, we tested the effects of a potent antiplatelet agent given both before and after the onset of middle cerebral arterial (MCA) occlusion in a murine model of stroke. After 45 min of MCA occlusion and 23 h of reperfusion, fibrin accumulates in the ipsilateral cerebral hemisphere, based upon immunoblotting, and localizes to microvascular lumena, based upon immunostaining. In concordance with these data, there is a nearly threefold increase in the ipsilateral accumulation of 111In-labeled platelets in mice subjected to stroke compared with mice not subjected to stroke. When a novel inhibitor of the glycoprotein IIb/IIIa receptor (SDZ GPI 562) was administered immediately before MCA occlusion, platelet accumulation was reduced 48%, and fibrin accumulation was reduced by 47% by immunoblot densitometry. GPI 562 exhibited a dose-dependent reduction of cerebral infarct volumes measured by triphenyltetrazolium chloride staining, as well as improvement in postischemic cerebral blood flow, measured by laser doppler. GPI 562 caused a dose-dependent increase in tail vein bleeding time, but intracerebral hemorrhage (ICH) was not significantly increased at therapeutic doses; however, there was an increase in ICH at the highest doses tested. When given immediately after withdrawal of the MCA occluding suture, GPI 562 was shown to reduce cerebral infarct volumes by 70%. These data support the hypothesis that in ischemic regions of brain, microvascular thrombi continue to accumulate even after recanalization of the MCA, contributing to postischemic hypoperfusion and ongoing neuronal damage.
急性中风的治疗选择受到限制,原因在于缺乏安全有效的方案来使闭塞的脑血管分支再通,而且患者往往在闭塞事件发生后才前来就诊。我们推测,即使中风后主要动脉闭塞部位实现了再通,微血管血栓仍会在远端部位持续形成,减少缺血后血流,并导致神经元持续死亡。为了验证这一假设,并证明微血管血栓形成是中风发作后持续的动态过程,我们在小鼠中风模型中测试了一种强效抗血小板药物在大脑中动脉(MCA)闭塞发作前后给药的效果。在MCA闭塞45分钟和再灌注23小时后,基于免疫印迹法,纤维蛋白在同侧脑半球中积累,基于免疫染色法,其定位于微血管管腔。与这些数据一致,与未发生中风的小鼠相比,中风小鼠同侧111In标记血小板的积累增加了近三倍。当在MCA闭塞前立即给予一种新型糖蛋白IIb/IIIa受体抑制剂(SDZ GPI 562)时,通过免疫印迹光密度测定法,血小板积累减少了48%,纤维蛋白积累减少了47%。通过氯化三苯基四氮唑染色测量,GPI 562呈现出剂量依赖性的脑梗死体积减小,通过激光多普勒测量,缺血后脑血流量也有所改善。GPI 562导致尾静脉出血时间呈剂量依赖性增加,但在治疗剂量下脑出血(ICH)并未显著增加;然而,在测试的最高剂量下ICH有所增加。当在撤出MCA闭塞缝线后立即给予GPI 562时,其可使脑梗死体积减少70%。这些数据支持了以下假设:在脑缺血区域,即使MCA再通后微血管血栓仍会继续积累,导致缺血后灌注不足和神经元持续损伤。